Life sciences companies have decided to chop hundreds of Bay Area jobs in a fresh wave of layoffs that hint at ongoing ...

Gilead is laying off 149 workers in Foster City and Roche is laying off 108 workers in Santa Clara, adding to the mounting ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

Riyadh, October 12, 2022, SPA -- King Faisal Specialist Hospital & Research Center (KFSHRC) has signed a memorandum of understanding with Kite-Gilead Sciences Company to cooperate in clinical research ...

Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an intramuscular injection given as two once-yearly formulations for pre-exposure ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

This month, Lila Sciences went public with its own ambitions to revolutionize science through A.I. The start-up, which is based in Cambridge, Mass., had worked in secret for two years “to build ...